156 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
Will be Reinvested to Fund Innovation and Drive Growth
Updating 2024 Non-GAAP EPS and Line-Item Guidance to Reflect Impact of Recently Completed Transactions … billion in cost savings by the end of 2025, the majority of which will be reinvested to fund innovation and drive growth.
As a part of this initiative
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our Values Innovation Passion … fortune 100 companies that have invested $1 billion with diverse-owned suppliers 3
4 Delivering Sustainable Growth and Innovation $45.0B Total
424B5
8l1fxf2
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
2rqui
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.1
c821a8m88 2dm
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
8-K
EX-99.1
70eng3i27dxb8y
8 Jan 24
Regulation FD Disclosure
10:29am
SC TO-C
EX-99.2
7dc10hjbfpml1p
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.5
w6tus408wkw2mhn 6op
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.1
4dekn1o8qdk
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.4
n9xpded
26 Dec 23
Information about tender offer
4:22pm
DFAN14A
EX-99.1
n49isys7fniu2rvxoa
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
zq8x48b y1d8fxv3yrqf
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
424B5
39ftp
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
gntbdc
30 Oct 23
Prospectus supplement
8:05am
DFAN14A
t8dbmyp1fru0pxh 4som
10 Oct 23
Additional proxy materials by non-management
6:48am